Natalia N. Petenko

Dr. Natalia N. Petenko


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KOKristina Orlova
Kristina Orlova
ELEvgeniy V. Ledin
Evgeniy V. Ledin
NZNatalia Zhukova
Natalia Zhukova
RORashida V. Orlova
Rashida V. Orlova
EKElena V. Karabina
Elena V. Karabina
LDLev V. Demidov
Lev V. Demidov
Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival rates. However, real-world data on treatment patterns and clinical outcomes for patients with advanced BRAF V600 mutant melanoma are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 patients with advanced BRAF V600 mutant melanoma, who received TT in a real-world setting and were not involved in clinical trials. The data were collected from twelve medical centers in Russia. The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy; 9.4 months and 16.1 months, respectively, for the combined second-line therapy; and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile.

4 May 2025 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
KOKristina Orlova
Kristina Orlova
MMMargarita V. Martynova
Margarita V. Martynova
NPNatalia N. Petenko
Natalia N. Petenko
VNValeria V. Nazarova
Valeria V. Nazarova
LDLev V. Demidov
Lev V. Demidov
Background. Basal cell skin carcinoma (BCSC) is the most common skin cancer. Most cases are diagnosed early and successfully treated using local methods. However, a small proportion of patients develop locally advanced or metastatic BCRCs, which is a challenging clinical issue. The number of locally advanced and/or metastatic forms of BCSCs is based on the experience of individual centers or the analysis of individual databases because the skin cancer cases generally are coded and accounted under the C44 category without counting separately the nosological forms and data on the disease prevalence. Aim. To estimate the number of patients with locally advanced and metastatic BCRCs among all patients treated in the N.N. Blokhin National Medical Research Center of Oncology from 2019 to July 2024 with the diagnosis code C44 according to the International Classification of Diseases, 10th Edition. Results. Between 2019 and July 2024, 3,801 individual cases of non-melanoma skin cancer (C44) were reported. Most of the 3,801 patients had BCSCs (n=2,796, 73.6%), followed by squamous cell carcinoma (n=857, 22.5%), Merkel cell carcinoma (n=100, 2.6%), and other skin tumors and neoplasms originating from the skin appendages (n=48, 1.3%). Among all cases of BCSCs, 94 (3.4%) cases of locally advanced and metastatic forms of the disease were reported. These patients were divided into two groups: with locally advanced BCSC (78 patients, 2.8%) and metastatic BCSC (16 patients, 0.6%). Conclusion. Most patients with early stages of BCSCs can be completely cured with radical surgery and/or radiation therapy, and a small number of patients develop disease progression that is not amenable to surgery or radiation therapy. We obtained the following results: 2.8% of locally advanced BCSCs and 0.6% of metastatic BCSCs, which is consistent with the literature data, where locally advanced BCSCs are reported in 1-2% of patients, and BCSC metastasis is reported in 0.0028-0.55%.

10 April 2019 in Malignant tumours
Verified
Journal Article
Open access
PDF file
KOK. V. Orlova
K. V. Orlova
VNV. V. Nazarova
V. V. Nazarova
NPNatalia N. Petenko
Natalia N. Petenko
LDL. V. Demidov
L. V. Demidov
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer with limited treatment options in later stages, when the mortality rate due to the disease is as high as 46 %. It has been demonstrated earlier that MCC is an immunogenic tumor, therefore the emergence of immune checkpoint inhibitors has changed the treatment principles for patients with advanced MCC. In this article, we present the initial results of the use of avelumab, an anti‑PD–L1 antibody, in the treatment of patients with metastatic and/or locally advanced MCC as part of the early access program in Russia.

27 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TBTatiana Belysheva
Tatiana Belysheva
TNTatiana Nasedkina
Tatiana Nasedkina
EZEkaterina Zelenova
Ekaterina Zelenova
VSVera Semenova
Vera Semenova
PSPeter Sparber
Peter Sparber
SVSvetlana Varfolomeeva
Svetlana Varfolomeeva
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are rare autosomal recessive DNA repair disorders. XP is characterized by extreme sensitivity to UV-radiation and a very high risk of skin cancer. To date, little is known about the clinical characteristics and genetic basis of these diseases in Russia. Here, we present a detailed study of 14 patients (aged 5–30 years) from 11 unrelated families of diverse ethnic backgrounds. Using a multigene panel or whole-genome sequencing, we identified homozygous or compound heterozygous variants in XPC (8 patients) and XPA (3 patients). In one family with two XP cases, a patient with CS and compound heterozygous ERCC6 variants was identified. In total, 110 family members were screened to determine their carrier status. Skin cancer was revealed in 12/13 (92%) of XP patients, with a median age at diagnosis of 12.5 years (range 5–22). Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma developed in 10, 6, and 3 patients, respectively. All three cancer types occurred in 2 patients. All patients underwent surgical treatment; additionally, two patients with BCC received targeted therapy (vismodegib, sonidegib). Anti-PD-1 immunotherapy was administered with a favorable clinical response in three patients with advanced SCC or melanoma.

17 May 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
KOKristina Orlova
Kristina Orlova
NPNatalia N. Petenko
Natalia N. Petenko
NGNatalia V. Garanina
Natalia V. Garanina
LDLev V. Demidov
Lev V. Demidov
Background. The need to use BRAF and MEK inhibitors in the treatment of patients with metastatic and/or unresectable BRAF + melanoma in certain clinical situations is beyond doubt nowadays. The medical community need more information about the new combination of targeted therapy approved in Russia, further details on the expected efficacy and tolerability, potential differences from the existing combinations. Aim. To present of the study results and demonstration of our experience with the new generation of targeted therapy encorafenib and binimetinib combination in the treatment of patients with metastatic and/or inoperable BRAF+ melanoma. Materials and methods. We present the clinical case of BRAF+ advanced melanoma patient with multiple metastases in the liver, spleen, mediastinal and abdominal lymph nodes, stomach and bones who is being treated with encorafenib and binimetinib since 2015 with the treatment efficacy and tolerability described in details, as well as the published data on the efficacy and tolerability of this combination from the pivotal phase III study COLUMBUS. Results. High immediate and long-term efficacy, satisfactory tolerability of encorafenib and binimetinib combination are presented. Updated data on progression-free and overall survival in the COLUMBUS study confirmed the long-term efficacy of COMBO450 therapy in patients with advanced melanoma with BRAF V600 mutation. Conclusion. New generation of BRAFi and MEKi combination expands options of systemic therapy for patients with metastatic and/or inoperable BRAF+ melanoma.

14 June 2023 in Effective Pharmacotherapy
Verified
Journal Article
Closed access
NPNatalia N. Petenko
Natalia N. Petenko
NON.N. Blokhin National Medical Research Center of Oncology
N.N. Blokhin National Medical Research Center of Oncology
KOK.V. Orlova
K.V. Orlova
VNV.V. Nazarova
V.V. Nazarova
IFIu.A. Filippova
Iu.A. Filippova
RURUDN University
RUDN University
Синдром Горлина – Гольца – редкая наследственная патология, которая характеризуется широким спектром аномалий развития и предрасположенностью к возникновению злокачественных опухолей